top of page

SUBSCRIBE TO OUR NEWSLETTER

THE LATEST NEWS IN CANCER CLINICAL RESEARCH

AT MEDSIR WE ARE DEDICATED TO OFFER THE MOST RELEVANT NEWS ON THE LATEST ADVANCEMENTS IN ONCOLOGY CLINICAL RESEARCH. FIND OUT THE LATEST NEWS ON ONCOLOGY RESEARCH, REGULATORY APPROVALS, EVENTS, SCIENTIFIC CONFERENCES AND MUCH MORE!

DOWNLOAD COMPANY DOSSIER

Search

We spoke with Roldán Cortés, Director of Development and Marketing of MEDSIR

We spoke with Roldán Cortés, Director of Development and Marketing of MEDSIR

We spoke with Roldán Cortés, Director of Development and Marketing of MEDSIR

Apr 19, 20216 min read

We granted a video interview to PM Farma

We granted a video interview to PM Farma

We granted a video interview to PM Farma

Apr 14, 20211 min read

Accelerate therapeutic innovation with clinical trials

Accelerate therapeutic innovation with clinical trials

Accelerate therapeutic innovation with clinical trials

Apr 13, 20212 min read

CAILA Study (breast)

CAILA Study (breast)

CAILA Study (breast)

Apr 13, 20211 min read

ORPHEUS Study (penile)

ORPHEUS Study (penile)

ORPHEUS Study (penile)

Mar 22, 20211 min read

Cancer Network presents MEDSIR’s study Phergain-2

Cancer Network presents MEDSIR’s study Phergain-2

Cancer Network presents MEDSIR’s study Phergain-2

CANCER RESEARCH

Mar 18, 20211 min read

EXCAAPE Study (prostate cancer)

EXCAAPE Study (prostate cancer)

EXCAAPE Study (prostate cancer)

Mar 15, 20211 min read

PECATI: New clinical trial with pembrolizumab and lenvatinib for patients with advanced thymic tumor

PECATI: New clinical trial with pembrolizumab and lenvatinib for patients with advanced thymic tumor

PECATI: New clinical trial with pembrolizumab and lenvatinib for patients with advanced thymic tumor

Feb 18, 20213 min read

PECATI Study (thymic carcinoma)

PECATI Study (thymic carcinoma)

PECATI Study (thymic carcinoma)

Feb 11, 20212 min read

PHERGain-2 Study (Breast)

PHERGain-2 Study (Breast)

PHERGain-2 Study (Breast)

Feb 4, 20211 min read

PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients

PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients

PHERGain-2: a study of a new therapeutic strategy to avoid chemotherapy in breast cancer patients

Feb 3, 20213 min read

IASLC 2020 World Conference on Lung Cancer: LUPER initiated trial to be presented

IASLC 2020 World Conference on Lung Cancer: LUPER initiated trial to be presented

IASLC 2020 World Conference on Lung Cancer: LUPER initiated trial to be presented

CANCER RESEARCH

Jan 26, 20213 min read

Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS

Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS

Interview with Dr. Llombart on OncologyTube on the PARSIFAL and BIOPER studies presented at SABCS

Jan 18, 20212 min read

Stage I in LUZERN Study completed!

Stage I in LUZERN Study completed!

Stage I in LUZERN Study completed!

Jan 5, 20212 min read

Results of our BIOPER study were presented at SABCS 2020

Results of our BIOPER study were presented at SABCS 2020

Results of our BIOPER study were presented at SABCS 2020

CANCER RESEARCH

Dec 17, 20203 min read

Final safety results of our PARSIFAL study were presented at SABCS 2020

Final safety results of our PARSIFAL study were presented at SABCS 2020

Final safety results of our PARSIFAL study were presented at SABCS 2020

Dec 14, 20202 min read

SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented

SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented

SABCS 2020: Final results of PARSIFAL and BIOPER clinical trials to be presented

Dec 4, 20202 min read

Interviewing Dr. Ana López on MEDSIR REVERT TRIAL (advanced metastatic breast cancer)

Interviewing Dr. Ana López on MEDSIR REVERT TRIAL (advanced metastatic breast cancer)

Interviewing Dr. Ana López on MEDSIR REVERT TRIAL (advanced metastatic breast cancer)

Nov 18, 20203 min read

A new milestone achieved in LUZERN Study: 75% recruitment on stage I

A new milestone achieved in LUZERN Study: 75% recruitment on stage I

A new milestone achieved in LUZERN Study: 75% recruitment on stage I

Nov 9, 20202 min read

COPERNICO Study has reached 29% recruitment

COPERNICO Study has reached 29% recruitment

COPERNICO Study has reached 29% recruitment

Nov 9, 20202 min read

First Patient Enrolled In ZZ-First Study

First Patient Enrolled In ZZ-First Study

First Patient Enrolled In ZZ-First Study

Nov 2, 20202 min read

SEOM 2020: Results from the Spanish cohort of the MEDSIR-sponsored study PARSIFAL

SEOM 2020: Results from the Spanish cohort of the MEDSIR-sponsored study PARSIFAL

SEOM 2020: Results from the Spanish cohort of the MEDSIR-sponsored study PARSIFAL

CANCER RESEARCH

Oct 22, 20202 min read

Results of the PARSIFAL study to be presented at the SEOM Conference 2020

Results of the PARSIFAL study to be presented at the SEOM Conference 2020

Results of the PARSIFAL study to be presented at the SEOM Conference 2020

CANCER RESEARCH

Oct 14, 20202 min read

First enrollment in the PATHFINDER study

First enrollment in the PATHFINDER study

First enrollment in the PATHFINDER study

Oct 13, 20202 min read

bottom of page